Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (253)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Pamiparib |
PARP Inhibitor | Solid Tumour | ||
|
Molecule
Pamiparib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
||||
Panobinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Panobinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Patidegib |
Hedgehog Pathway Inhibitor | Solid Tumour / Hematologic (AML) | ||
|
Molecule
Patidegib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
||||
Pazopanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Pazopanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Pemigatinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Pemigatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Peposertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Peposertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
Pexmetinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Pexmetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
PF-06821497 (EZH2 Inhibitor) |
EZH2 Inhibitor | Hematologic | ||
|
Molecule
PF-06821497 (EZH2 Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
||||
Pictilisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Pictilisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Pilaralisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Pilaralisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Pimasertib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Pimasertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Pirtobrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Pirtobrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
PamiparibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
|
PanobinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
PatidegibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
|
PazopanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
PemigatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
PeposertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|
PexmetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
PF-06821497 (EZH2 Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
|
PictilisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
PilaralisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
PimasertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
PirtobrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|